Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 2/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178900 | 0.78 | HMGCR (0.52) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL83915 | 0.75 | TSHR (0.60) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| Hydrochloric Acid SCHEMBL4137653 | 0.75 | TSHR (0.60) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| Ammonia Solution, Strong SCHEMBL10868076 | 0.72 | TSHR (0.57) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| Ammonia Solution, Strong SCHEMBL10870096 | 0.72 | TSHR (0.57) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL6739451 | 0.72 | TSHR (0.57) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL8844260 | 0.72 | TSHR (0.57) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL28478983 | 0.72 | TSHR (0.57) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| T-Butylacetic Acid SCHEMBL734659 | 0.71 | — | — | |
| T-Butylacetic Acid SCHEMBL9222635 | 0.71 | HMGCR (0.58) | HMGCRCHRM1TBXA2RADRA1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20060063774-A1 | Phosphodiesterase inhibitor compounds and nitric oxide donors | GARVEY DAVID S | 2006-03-23 | — | — | US | disclosed |
| EP-1109543-A4 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6930113-B2 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | GARVEY DAVID S (US) | 2004-05-06 | — | — | US | disclosed |
| US-20030158184-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | GARVEY DAVID S (US) | 2003-08-21 | — | — | US | disclosed |
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2003-01-30 | — | — | US | disclosed |
| US-6472425-B1 | Methods for treating female sexual dysfunctions | NITROMED, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6462044-B2 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2002-02-14 | — | — | US | disclosed |
| US-6331543-B1 | TREATING SEXUAL DYSFUNCTION | NITROMED, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1109543-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | HMGCR 456/4885CHRM1 219/4885TBXA2R 1204/4885 |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | HMGCR 456/4885CHRM1 219/4885TBXA2R 1204/4885 |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | HMGCR 1709/4885CHRM1 427/4885TBXA2R 131/4885 |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE5A | HMGCR 473/4885CHRM1 302/4885TBXA2R 802/4885 |
| US-20030158184-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses | PDE3A, PDE3B, PDE2A | HMGCR 1184/4885CHRM1 374/4885TBXA2R 214/4885 |
| US-20060063774-A1 | Phosphodiesterase inhibitor compounds and nitric oxide donors | PDE3B, PDE3A, PDE5A | HMGCR 1205/4885CHRM1 1512/4885TBXA2R 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.